Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innate PharmaIPHA +0.57%41 Equity-to-Asset is -0.35 as of Dec. 2025. GuruFocus rates IPHA with a GF Score™ of 41/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Innate Pharma ranks worse than 90.47% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Innate Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-25.42 Mil. Innate Pharma's Total Assets for the quarter that ended in Dec. 2025 was $73.44 Mil.
Therefore, Innate Pharma's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was -0.35.
The historical rank and industry rank for Innate Pharma's Equity-to-Asset or its related term are showing as below:
IPHA'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.35 Med: 0.32 Max: 0.54
Current: -0.35
During the past 13 years, the highest Equity to Asset Ratio of Innate Pharma was 0.54. The lowest was -0.35. And the median was 0.32.
IPHA's Equity-to-Asset is ranked worse than 90.47% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs IPHA: -0.35
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Innate Pharma Equity-to-Asset Related Terms
Innate Pharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Innate Pharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPHA vs VRTX, REGN, ALNY: Equity-to-Asset Comparison
For the Biotechnology subindustry, Innate Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innate Pharma Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innate Pharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Innate Pharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Innate Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innate Pharma (IPHA) has a Equity-to-Asset of -0.35 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Innate Pharma and its competitors. According to the industry distribution chart, Innate Pharma ranks #1281 out of 1416 companies in the Biotechnology industry, placing it in the top 90.5%.
Is Innate Pharma's Equity-to-Asset too high?
Innate Pharma's current Equity-to-Asset is -0.35. Based on the distribution chart, Innate Pharma ranks #1281 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innate Pharma ranks #1281 out of 1416 companies for Equity-to-Asset. This places Innate Pharma in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Innate Pharma and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innate Pharma's current Equity-to-Asset is -0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.78 — trading 1009.4% above its estimated fair value. The current Equity-to-Asset is -0.35. Innate Pharma's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Equity-to-Asset is -0.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.78 is trading 1009.4% above its estimated GF Value™ of $0.16.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
Equity-to-Asset: -0.35
GF Value™: $0.16 vs. price of $1.78 (1009.4% above fair value)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score
Get the complete analysis for IPHA
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
